


The burden of antimicrobial resistance (AMR) in Bolivia (Plurinational State of)

Executive summary

- Antimicrobial Resistance (AMR) is a major global health threat, over **2,000 lives** have been lost each year since 1990 in Bolivia (Plurinational State of) due to AMR.
- In 2021, there were an estimated **1,610 UI (1,240-1,980)** deaths attributable to AMR and **6,630 UI (5,050-8,200)** deaths associated with AMR in this location.
- The largest number of deaths associated with AMR in 2021 occurred among those aged **70+** in the country.
- Among the most deadly pathogen-drug combinations in 2021 were *Staphylococcus aureus* resistant to methicillin, *Pseudomonas aeruginosa* resistant to carbapenems and *Klebsiella pneumoniae* resistant to third-generation cephalosporins.

Figure 1 Number of deaths by underlying cause, and those associated with AMR in 2021




- In 2021, the number of deaths associated with AMR (orange bar in *figure 2*) were high compared to the most relevant underlying causes of death (depicted in blue) in the country. AMR associated deaths occur within multiple Global Burden of Disease (GBD) causes of death and AMR is not an underlying cause of death by itself.
- At the [2024 United Nations General Assembly high level meeting on antimicrobial resistance](#), country members agreed to aim for a **10% reduction** compared to 2019 baseline (**from 4.95 to 4.45 million**) in the global number of deaths associated with AMR by 2030. But [our forecast](#) indicates that in absence of concerted action, deaths associated with AMR could reach **5.5 million** (UI 4.8 - 6.2) if current trends continue. For Bolivia, a 10% reduction means to decrease the number of deaths associated with AMR to **6,800**, but currently the trend for this country could reach up to **8,200 UI [6,170-11,000]** AMR-associated deaths in 2030.

AMR in Bolivia (Plurinational State of)

Key takeaways

- Antimicrobial Resistance (AMR) is a major global health threat, over *a million lives* have been lost each year since 1990.
- Globally, 4.71 (95% Uncertainty Interval (UI) 4.2-5.2) million deaths were associated with bacterial drug-resistant infections in 2021.
- And 1.14 (UI 1 - 1.3) million deaths were attributable to bacterial drug-resistant infection in the same year.
- *39 (UI 33 - 46) million deaths* directly attributable to bacterial AMR are projected to occur between 2025-2050 unless concerted action is taken. This equates to three deaths every minute.

Figure 2 Comparing 30 years of infection related deaths, and those associated with and attributable to AMR in Bolivia (Plurinational State of) between 1990 and 2019.



- To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#)
- In **Bolivia (Plurinational State of)** in 2021, there were an estimated **1,610 UI (1,240-1,980)** deaths attributable to AMR and **6,630 UI (5,050-8,200)** deaths associated with AMR. Here “*attributable deaths*” are considered to be those that would have been prevented had the drug-resistant bacteria causing the infections not been drug-resistant. “*Associated deaths*” are considered to be those that would not have occurred had the infections been prevented entirely.
- Across 204 countries, **Bolivia (Plurinational State of)** has the **71st highest** age-standardized mortality rate associated with AMR in 2021.
- *Table 1* shows the bacteria which caused most deaths in 2021 (↑ indicates an increasing estimated annual rate between 1990-2021, ↓ indicates a decreasing annual trend), and *table 2* shows the pathogen-drug combinations which caused most deaths in 2021.

Table 1. Bacteria which cause most deaths in 2021 (Number of deaths in parenthesis)

	Overall susceptible and resistant	Associated	Attributable
Burden rank	Streptococcus pneumoniae 1,630 UI (1,280-1,980) ↓	Klebsiella pneumoniae 1,160 UI (882-1,430) ↓	Klebsiella pneumoniae 307 UI (233-380) ↓
	Staphylococcus aureus 1,570 UI (1,210-1,920) ↑	Staphylococcus aureus 1,040 UI (782-1,300) ↑	Staphylococcus aureus 305 UI (214-397) ↑
	Klebsiella pneumoniae 1,520 UI (1,180-1,870) ↓	Escherichia coli 1,010 UI (775-1,240) ↑	Pseudomonas aeruginosa 213 UI (146-280) ↓
	Mycobacterium tuberculosis 1,480 UI (981-1,980) ↓	Pseudomonas aeruginosa 868 UI (644-1,090) ↓	Acinetobacter baumannii 199 UI (158-239) ↓
	Pseudomonas aeruginosa 1,210 UI (929-1,480) ↑	Streptococcus pneumoniae 820 UI (499-1,140) ↓	Escherichia coli 192 UI (139-244) ↑
	Escherichia coli 1,150 UI (888-1,400) ↑	Acinetobacter baumannii 550 UI (418-683) ↓	Streptococcus pneumoniae 144 UI (76-212) ↓
	Acinetobacter baumannii 606 UI (463-750) ↓	Enterobacter spp. 180 UI (129-230) ↓	Mycobacterium tuberculosis 56 UI (0-169) ↑
	Group B Streptococcus 294 UI (232-357) ↓	Mycobacterium tuberculosis 163 UI (36-417) ↑	Enterobacter spp. 39 UI (29-50) ↓
	Enterobacter spp. 274 UI (209-339) ↑	Proteus spp. 156 UI (107-204) ↑	Serratia spp. 39 UI (29-49) ↓
	Serratia spp. 264 UI (203-325) ↓	Serratia spp. 150 UI (110-191) ↓	Enterococcus faecium 29 UI (20-38) ↑

Annualized rate of change (1990-2021): <-3% (dark blue), -3% to -1.5% (medium blue), -1.5% to 0% (light blue), 0% to 1.5% (pink), 1.5% to 3% (red), 3% to 5% (dark red), >5.0% (black)


Table 2. Combinations which cause most deaths in 2021 (Number of deaths in parenthesis)

	Associated	Attributable
Burden Rank	Klebsiella pneumoniae 3GC 1,090 UI (843-1,340) ↓	Staphylococcus aureus Methicillin 239 UI (148-329) ↑
	Staphylococcus aureus Methicillin 929 UI (585-1,270) ↑	Klebsiella pneumoniae 3GC 89 UI (51-126) ↓
	Klebsiella pneumoniae Aminoglycosides 919 UI (677-1,160) ↓	Pseudomonas aeruginosa Carbapenems 71 UI (36-106) ↑
	Escherichia coli Aminopenicillin 898 UI (559-1,240) ↑	Klebsiella pneumoniae Aminoglycosides 67 UI (44-90) ↓
	Klebsiella pneumoniae TMP-SMX 817 UI (572-1,060) ↓	Pseudomonas aeruginosa Fluoroquinolones 66 UI (43-89) ↓
	Klebsiella pneumoniae Fluoroquinolones 802 UI (563-1,040) ↑	Acinetobacter baumannii Fluoroquinolones 62 UI (48-76) ↑
	Escherichia coli Fluoroquinolones 721 UI (446-996) ↑	Klebsiella pneumoniae Fluoroquinolones 60 UI (38-82) ↑
	Escherichia coli TMP-SMX 705 UI (512-899) ↓	Klebsiella pneumoniae Carbapenems 59 UI (41-77) ↑
	Pseudomonas aeruginosa Fluoroquinolones 701 UI (523-878) ↓	Acinetobacter baumannii Anti-pseudomonal 58 UI (44-71) ↓
	Klebsiella pneumoniae Beta-Lactam/Lactamase Inhib. 690 UI (425-956) ↓	Mycobacterium tuberculosis MDR excluding XDR 46 UI (0-145) ↑

Annualized rate of change (1990-2021): <-3% (dark blue), -3% to -1.5% (medium blue), -1.5% to 0% (light blue), 0% to 1.5% (pink), 1.5% to 3% (red), 3% to 5% (dark red), >5.0% (black)

- Independently of antimicrobial resistance, the infectious syndromes accounting for the most deaths in 2021 were as follows (estimated thousands of deaths in parenthesis) lower respiratory infection (excl. COVID) (6,960 UI (5,410-8,510)), bloodstream infections (5,000 UI (3,860-6,140)), tuberculosis (1,480 UI (981-1,980)), peritoneal and intra-abdominal infections (1,060 UI (691-1,420)) and urinary tract infections and pyelonephritis (875 UI (652-1,100)).

Figure 3. Number of deaths associated with AMR by age group between 1990-2020 and 2050 projection



- In Bolivia (Plurinational State of), people aged under 5 experienced the largest number of deaths associated with AMR in 1990 but this changed by 2021 as the largest number of deaths occurred among the 70+. This indicates that prevention of infections among the under 5 has contributed to the reduction in the number of AMR associated deaths. In 2021, the number of deaths associated with AMR among the 70+ was 3,110 UI (2,450-3,760), whereas the mortality rate per 100,000 was 671 UI (530-813).

Data sources for Bolivia (Plurinational State of)

In total, 520 million individual records or isolates covering 19,513 study-location-years were used as input data to our estimation process. The subset of input data for this country is shown below.

Table 3. Data inputs for Bolivia (Plurinational State of) by source type

Source type	Years	Sample size	Sample size units
Antibiotic use	1990-2009	1,650	Study-year datapoints
Microbial or laboratory data without outcome	2010-2021	30	Isolates
Literature studies	1990-2009	79	Cases/isolates/susceptibility tests
Single drug resistance profile data	1990-2021	120,833	Antibiotic susceptibility test

More information

About GRAM:

The purpose of the Global Research on AntiMicrobial resistance (GRAM) project is to **generate accurate and timely estimates of the magnitude and trends in antimicrobial resistance (AMR) burden** across the world, which can be used to inform treatment guidelines and agendas for decision-making and research, detect emerging problems and monitor trends to inform global strategies, as well as facilitate the assessment of interventions over time.

GRAM is the flagship project of the University of Oxford–IHME Strategic Partnership. GRAM was launched with support from the United Kingdom Department of Health and Social Care’s Fleming Fund, and the Wellcome Trust.

All resources:

For all resources on AMR analysis at IHME, visit <https://www.healthdata.org/antimicrobial-resistance>.

To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#).

Data sources:

To download the list of data input sources by country, and AMR results by region, visit the [Global Health Data Exchange \(GHDx\)](#).

Contact us:

- For inquiries about the analysis and questions from government officials, health departments, or research institutions: engage@healthdata.org
- For media-related inquiries: media@healthdata.org
- **Bluesky:** @ihmeuw.bsky.social
- **Twitter:** @IHME_UW
- **Facebook:** <https://www.facebook.com/IHMEUW>
- **LinkedIn:** <https://www.linkedin.com/company/institute-for-health-metrics-and-evaluation>